Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate

NCT00928317 is registered in ClinicalTrials.gov with Arana Therapeutics Ltd as lead sponsor.

NCT NCT00928317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00928317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate
Lead sponsor
Arana Therapeutics Ltd
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2009
Completion date
December 31, 2009
Enrollment
13 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis